TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02933762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
Study: NCT00017537

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVF-HER-2(628-647)-CRL 1005 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVF-HER-2(628-647)-CRL 1005 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVF-HER-2(628-647)-CRL 1005 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVF-HER-2(628-647)-CRL 1005 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVF-HER-2(628-647)-CRL 1005 vaccine
Study: NCT01721811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Study: NCT04146506

Intervention type: OTHER
Intervention: Muscle stretching exercises
Description: Muscle stretching exercises consisting of static stretching exercises of the knee flexors

Intervention type: OTHER
Intervention: Muscle stretching exercises
Description: Muscle stretching exercises consisting of static stretching exercises of the knee flexors
Study: NCT03477552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein V400 device
Description: Sickle cell patients who need a new vein puncture in order to infuse them will benefit of AccuveinV400 device to illuminate their venous network

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine procedure
Description: In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
Study: NCT02522572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Plerixafor will be dosed subcutaneously and administered based on group assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Plerixafor will be dosed subcutaneously and administered based on group assignment.
Study: NCT04707976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navina Smart
Description: CE-marked NavinaTM Smart including Navina Smart App.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bowel Care
Description: Bowel care will be scheduled at least every 2nd day according to a defined study specific standard bowel care protocol. Diet, fluids, abdominal massage, regular physical activity and medications will be used if non-interventional treatment is insufficient.
Study: NCT00423319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Subcutaneous, 40 mg, once daily, 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Oral tablets, 2.5 mg, twice daily, 5weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin-matching placebo
Description: Administered as injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban-matching placebo
Description: Administered as oral tablets
Study: NCT03490448

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: aerobic exercise and appropriate caloric control
Description: The dietary was designed on the basis of ensuring the daily energy physiological requirement, and basal metabolic rate (BMR) was calculated to formulate diet project according to Harris-Benedict formula. The diet was composed of 20% protein, 30% fat and 50% carbohydrates.In the exercise, heart rate was monitored to ensure the small-medial load aerobic exercise. All kinds of sports were conducted indoor, twice per day, 6 days per week, and lasted for 2 hours every time.
Study: NCT00823121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: freezing embryos by vitrification
Description: vitrification by Cryotop method

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fresh embryo transfers
Description: fresh embryo transfers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin
Description: Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin
Description: Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin (pregnyl)
Description: hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin (pregnyl)
Description: hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
Study: NCT00336076

Intervention type: OTHER
Intervention: Collection of blood and bone marrow
Description: 5-8 cc blood or bone marrow was additionally collected for analysis during diagnostic procedures. No assigned interventions.
Study: NCT04408599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC410
Description: NC410 is an experimental antibody drug that may make the immune response more active against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC410
Description: NC410 is an experimental antibody drug that may make the immune response more active against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC410
Description: NC410 is an experimental antibody drug that may make the immune response more active against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC410
Description: NC410 is an experimental antibody drug that may make the immune response more active against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC410
Description: NC410 is an experimental antibody drug that may make the immune response more active against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC410
Description: NC410 is an experimental antibody drug that may make the immune response more active against cancer
Study: NCT02202772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravesical instillation of Gemcitabine for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravesical instillation of Gemcitabine for 2 hours
Study: NCT02522572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Plerixafor will be dosed subcutaneously and administered based on group assignment.
Study: NCT04408599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC410
Description: NC410 is an experimental antibody drug that may make the immune response more active against cancer
Study: NCT01617694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Study: NCT02522572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Plasmapheresis will be administered based on group assignment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Plasmapheresis will be administered based on group assignment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Plasmapheresis will be administered based on group assignment.
Study: NCT00388323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and biopsies
Description: blood and biopsies
Study: NCT01478295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CuidaCare Intervention
Description: Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group/Usual Care:
Description: Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group/Usual Care:
Description: Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
Study: NCT01617694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Study: NCT01385982

Intervention type: OTHER
Group type: OTHER
Intervention: Actionable Test Result Management/Standardization
Description: The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
Study: NCT00573157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate mofetil
Description: MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
Study: NCT02448147

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous training
Description: Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
Study: NCT03084848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 25 training sessions of 15 minutes per day, 5 days a week for a month of crystallised intelligence
Study: NCT00573157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroids
Description: High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
Study: NCT03069898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRUE Dads
Description: The TRUE Dads intervention consists of a set of 12 3-hour workshops that focus on enhancing fathers' role as co-parent, parent, and provider
Study: NCT01027013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebamipide 2% ophthalmic suspension
Description: Instill one drop in each eye four times daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo eye drops
Description: Instill one drop in each eye four times daily for 12 weeks.
Study: NCT02072512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: goserelin 3.6mg subcutaneously every 28(± 3) days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: goserelin 3.6mg subcutaneously every 28(± 3) days
Study: NCT03130712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPC3-CART cells
Description: Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
Study: NCT02500368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silicone hydrogel lens (test)
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A lens (control)
Description: contact lens
Study: NCT00141856

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone care
Study: NCT02828696

Intervention type: DEVICE
Group type: OTHER
Intervention: No prep treatment of worn dentition with CAD-CAM composite
Description: Realization of minimally invasive prostheses in PICN (CAD-CAM composite)for worn dentition. Tooth tissues are preserved: no preparation is performed and ultra-thin restorations are CAD-CAM milled.
Study: NCT01007266

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assignment of a Lay Patient Partner

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assignment of a Lay Patient Partner
Study: NCT01944696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phototherapy
Description: Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
Study: NCT00532818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and magnesium valproate
Description: Cisplatin + Topotecan plus hydralazine valproate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cisplatin + Topotecan plus placebo
Study: NCT02202772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravesical instillation of Gemcitabine for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravesical instillation of Gemcitabine for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravesical instillation of Gemcitabine for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravesical installation of Cisplatin for 2hours
Study: NCT03795896

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optic nerve sheath diameter
Description: The intracranial pressure will be measured by the optic nerve sheath diameter and after giving the mannitol osmotherapy the intracranial pressure will be monitored by the optic nerve sheath diameter
Study: NCT02257541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study: NCT00140621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agalsidase beta
Study: NCT02452541

Intervention type: OTHER
Group type: OTHER
Intervention: Prognostic tests
Description: * Brain CT-Scan on day 1, 3 and 7~* Brain MRI on day 7~* SomatoSensory Evoked Potentials on day 7~* Electroencephalogram on day 7~* Serum biomarkers on day 1, 3 and 7~* Daily clinical exams
Study: NCT00902720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue sample storage
Description: The tissue sample is frozen and held at -140 degrees at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
Study: NCT03580174

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal directed physiotherapy group
Description: Ten children with CP will receive structural, comprehensive activity based, goal directed therapy protocol one hour in a session, 2 times in a week during 8 weeks. GDPT will be a structural protocol and consists of daily life activities as sit to stand and reach, treadmill exercises, balance exercises with bosu-ball, orthotics, home program, following with exercise-diary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy group
Description: Ten children with CP will RPT applications will consist of unstructured stretching exercises, massage, passive range of motions, muscle strengthening, orthotics etc.) one hour in a session, 2 times in a week during 8 weeks.
Study: NCT03084848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 25 training sessions of 15 minutes per day, 5 days a week for a month of inhibitory control
Study: NCT03738722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher\&Paykel.
Study: NCT03807388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReMindCare Intervention Group
Description: Daily and weekly assessments of patient´s health status, and generation of alarms related to these answers. Moreover, patients can contact clinicians by an urgent consultation tab.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Psychiatric usual treatment at First Episode of Psychosis Unit at Clinical Hospital of Valencia, Spain.
Study: NCT02961036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 information
Description: Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 information
Description: Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 3 information
Description: Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 4 information
Description: Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 5 no information
Description: Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A Reminder
Description: One survey reminder at 14 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B Reminders
Description: Two survey reminders one at 14 days and one at 28 days
Study: NCT02647476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunomodulating nutrition (Reconvan)
Description: protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutrition (Peptisorb)
Description: oligopeptide, low-fat, isocaloric, non-residue diet
Study: NCT01382914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chlorhexidine 0.12%
Description: twice daily, 10 ml, topical